Matthias Müllenbeck: What if we paid doctors to keep people healthy?
马提亚斯·穆兰贝克: 如果我们付钱给医生,让他们保持人民的健康,听起来如何?
As the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology. Full bio
Double-click the English transcript below to play the video.
酒店的客房中醒来,
fell off the evening before.
I'm sitting in a dentist's chair.
好让我脱离牙痛之苦,
so that I can get rid of my pain,
钛植牙手术的优点。
of a titanium implant surgery.
a damaged tooth
may add up to 10,000 US dollars.
可能会高达一万美金。
that could be earned with me
还是能从我身上赚到的钱,
for my dentist?
wasn't an isolated case.
estimated that in the United States,
在美国所有的手术当中,
surgical procedures --
and pacemaker implantations,
治疗方式尚未完全
options had not been fully exploited
in other countries,
if you go to a doctor in the US,
会在不立即需要手术的情况下
to be subjected to a surgical intervention
an immediate need for it.
to run such unnecessary procedures?
会被鼓励去做这类不必要的手术?
health care systems themselves
某些手术或治疗。
certain procedures or treatments.
reimburse practitioners
对从业医生的补助
of treatments performed,
诱使一些从业医生
that tempts some practitioners
surgical treatments
other treatment options.
started to implement
health care systems' architecture
系统结构中,很少会有某种方式,
of a disease in the first place
applied to a patient
system's architecture --
of the incentive structure.
for keeping their customers healthy
已患病之后的治疗服务。
once people are already sick.
that largely cares for the sick,
people once they have become sick
从在大家生病之后才进行治疗,
努力维持他们的健康。
before they get sick.
of all those involved --
所有相关群体的焦点发生改变——
to pharmaceutical and medical companies --
及医疗器材公司——
最终要销售的产品上:
ultimately sells:
reimburse practitioners
performed on a patient
individual is kept healthy
to an insurance company
is kept healthy
其他形式的急性医疗干预就付款。
of acute medical intervention.
所需要进行的医疗干预中
any further monetary compensation
to treat the disease of that individual,
for every evidence-based treatment option
让客户恢复健康的治疗选择,
will be paid again.
their customers healthy,
医疗干预,就能得到奖励,
any unnecessary medical interventions
that eventually become sick.
to treat the sick will be,
for all parties being involved
structure shifts, now,
health care system
且单一的治疗选择,
and singular treatment options,
to stay healthy and live long.
to share their health data
understands early enough
需要什么样的协助。
to their health is needed.
cardiometabolic profiling
and general practitioners,
以及身体活动相关的决策——
and their physical activity --
individual high-risk disease.
data analysis
of sensor technologies
个人健康状况成为可能。
of the individual health status possible.
by devices like this
测量心血管代谢参数,
tumor DNA in your bloodstream
就先检测你的血液中
两个例子而已。
for such monitoring technologies.
in certain oncological diseases
最大的问题之一,
is diagnosed too late
药品和治疗手段
that could potentially have cured them
been detected earlier.
based on a few milliliters of blood,
根据几毫升的血液
血液循环肿瘤DNA,
of circulating tumor DNA
detection can have
for non-small cell lung cancer
就诊断出来,五年存活率是49%。
which is early, is 49 percent.
at stage four, which is late,
也就是晚期才诊断出来,
to prevent a large number of deaths
比如血液循环肿瘤DNA的血液检测,
for circulating tumor DNA
癌症变成可以控制的疾病,
a manageable disease,
can likely be increased.
had a single chronic disease,
医疗预算中有86%
of the $3 trillion US health care budget
such chronic diseases.
to reduce this 86 percent,
还没有做出应对和改变?
not reacted and changed already?
is a sick care system
聚焦在预防和行为改变上的
that focuses on prevention
每个行为者都做出改变。
in the system to change.
to shift budgets and policies
and non-financial incentives.
和非经济上的奖励方式。
a regulatory framework
of personal health data
stringent and sensible.
pharmaceutical and medical companies
药厂,以及医疗器材公司
而且,最重要的是,
and, most important,
需要依靠每个人都有
the willingness and motivation
生活方式,变得更可持续,
in a sustained way,
经常分享健康数据。
the health data on a constant basis.
将奖励的焦点转变为
within the health care industry today
就先预防更多的疾病,
more diseases in the first place
某些可预防之疾病的发生,
the onset of certain preventable diseases
能更长寿、更健康。
and healthier lives for more people.
that we need to initiate that change
我们所需要的技术
ABOUT THE SPEAKER
Matthias Müllenbeck - Business developerAs the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology.
Why you should listen
Throughout his career in various roles at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck worked on strategic asset, technology and diagnostic-licensing deals and on bringing to market innovative chemical products. He holds a PhD in immunology from the Humboldt University in Berlin and has worked at the Max-Planck Institute for infection biology in Berlin, at Bayer, and at the Albert-Schweizer Hospital in Lambarané, Gabon.
Matthias Müllenbeck | Speaker | TED.com